A99 COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Ulcerative colitis (UC) is a relapsing and remitting condition, characterized by inflammation and ulceration in the colon and rectum. Biologic therapies have shown to be effective in inducing and maintaining remission in patients with UC, however there is no general consensus regarding which biologics should be used as first-line therapy for patients with UC. In order to decide which biologics should be used, the cost of the drugs needs to be taken into consideration. Infliximab, adalimumab, vedolizumab and golimumab are commonly used biologics for UC, however it is unknown which biologic is more cost-effective as first-line therapy for patients with moderate-to-severe disease. The aim of our study was to compare the cost-effectiveness of the commonly used biologics (infliximab, adalimumab, vedolizumab, golimumab) for the management of moderate-to-severe ulcerative colitis. A Markov model was constructed to simulate the clinical disease course of UC patients after initiating each biologic. Drug costs were obtained from the Alberta Health Drug Benefit List, and the remaining costs were determined from the CIHI Patient Cost Estimator. Transition probabilities were obtained from a review of the literature, and loss of response and complication rates for infliximab, adalimumab, vedolizumab and golimumab were obtained from the ACT, ULTRA, GEMINI, and PURSUIT trials, respectively. Previously published utility values were used to assess patient’s quality of life in each disease state. Our main analysis used a time horizon of 1 year due to the lack of long-term data on these therapies. Probabilistic sensitivity analysis was performed to characterize uncertainty related to all input parameters. Infliximab costs $31,405 per patient and yields 0.53 quality-adjusted life years (QALYs) using a 1-year time horizon. Adalimumab costs $25,191 per patient and yields 0.50 QALYs. Vedolizumab costs $30,338 per patient and yields 0.46 QALYs. Lastly, Golimumab costs $27,086 per patient and yields 0.51 QALYs. At a willingness-to-pay (WTP) threshold of $50,000 per QALY, probabilistic sensitivity analysis revealed that infliximab, adalimumab, vedolizumab, and golimumab had a 43%, 32%, 11%, and 14% probability of being cost-effective, respectively. Infliximab and adalimumab have a greater probability of being cost-effective as first-line therapies for patients with ulcerative colitis compared to vedolizumab and golimumab. None
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle